API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Coartem® (artemether-lumefantrine) a novel formulation which is being developed forthe treatment of babies weighing less than 5kg with malaria.
Lead Product(s): Artemether,Lumefantrine
Therapeutic Area: Infections and Infectious Diseases Product Name: Coartem
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.
Lead Product(s): Artemether,Lumefantrine,Amodiaquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GHIT Fund
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Financing December 13, 2023
Details:
KAF156 (Ganaplacide), belongs to a novel class of antimalarial molecules (imidazolopiperazines), has an effect on parasite internal protein secretory pathway. A key strength of the drug is its potential to both treat and prevent malaria, including resistant strains.
Lead Product(s): Ganaplacide,Lumefantrine
Therapeutic Area: Infections and Infectious Diseases Product Name: KAF156
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medicines for Malaria Venture
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2022